Capricor Faces Investor Scrutiny Following FDA Efficacy Dispute

The volatility stems from a sharp discrepancy between internal corporate reporting and federal regulatory findings. In a May 7, 2026, announcement, Capricor asserted that Deramiocel slowed cardiac decline by approximately 91% compared to a placebo, claiming the result reached statistical significance. However, the FDA’s subsequent review of the pivotal trial data concluded that the drug failed to demonstrate such benefits on its pre-specified cardiac endpoint.

Following the publication of these documents ahead of an advisory committee meeting, the market reacted aggressively, wiping out a significant portion of shareholder value. Levi & Korsinsky is currently reviewing the timeline of the company's public disclosures to determine if investors were misled by the initial efficacy claims. The firm is inviting shareholders who incurred losses to submit documentation, noting that eligibility for participation does not depend on whether the shares are still held or sold.